| Company Name: |
TargetMol |
| Tel: |
400-821-0310 15002144251 |
| Email: |
xuexiang.shao@tsbiochem.com |
|
| | Thalidomide-NH-amido-PEG1-C2-NH2 hydrochloride Basic information |
| Product Name: | Thalidomide-NH-amido-PEG1-C2-NH2 hydrochloride | | Synonyms: | Thalidomide-NH-amido-PEG1-C2-NH2 hydrochloride;Acetamide, N-[2-(2-aminoethoxy)ethyl]-2-[[2-(2,6-dioxo-3-piperidinyl)-2,3-dihydro-1,3-dioxo-1H-isoindol-4-yl]amino]-, hydrochloride (1:1);Pomalidomide-NH amido-PEG1-NH2(hydrochloride) | | CAS: | 2983036-29-7 | | MF: | C19H23N5O6.ClH | | MW: | 453.88 | | EINECS: | | | Product Categories: | | | Mol File: | 2983036-29-7.mol |  |
| | Thalidomide-NH-amido-PEG1-C2-NH2 hydrochloride Chemical Properties |
| | Thalidomide-NH-amido-PEG1-C2-NH2 hydrochloride Usage And Synthesis |
| Uses | Thalidomide-NH-amido-PEG1-C2-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology[1]. | | IC 50 | Cereblon | | References | [1] Sato T, et al. Cereblon-Based Small-Molecule Compounds to Control Neural Stem Cell Proliferation in Regenerative Medicine.Front Cell Dev Biol. 2021;9:629326. Published 2021 Mar 11. DOI:10.3389/fcell.2021.629326
[2] Nalawansha DA, et al. PROTACs: An Emerging Therapeutic Modality in Precision Medicine. Cell Chem Biol. 2020;27(8):998-985. DOI:10.7554/eLife.57277 |
| | Thalidomide-NH-amido-PEG1-C2-NH2 hydrochloride Preparation Products And Raw materials |
|